Intellia Therapeutics Inc.
NTLA | NASDAQ
$12.71
+$0.49 (+4.01%)
Sep 22, 2026, 2:11 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 67.67M | 57.88M | 36.28M | 52.12M | 33.05M | 57.99M |
Cost of Revenue | 15.92M | 10.29M | 8.98M | 7.57M | 6.89M | 150.41M |
Gross Profit | 51.75M | 47.59M | 27.3M | 44.55M | 26.16M | -92.41M |
Operating Income | -440.99M | -534.26M | -515.29M | -458.16M | -267.85M | -136.58M |
Interest Income | 29.2M | 47.81M | 49.83M | 8.54M | 1.28M | 2.35M |
Pretax Income | -412.69M | -519.02M | -481.19M | -474.19M | -267.89M | -134.23M |
Net Income | -412.69M | -519.02M | -481.19M | -474.19M | -267.89M | -134.23M |
Selling & General & Admin | 119.8M | 125.83M | 116.5M | 90.31M | 71.1M | 44.17M |
Research & Development | 388.86M | 466.31M | 435.07M | 419.98M | 229.81M | 150.41M |
Other Expenses | -15.92M | -10.29M | -8.98M | -7.57M | -6.89M | -150.41M |
Operating Expenses | 492.74M | 581.86M | 542.59M | 502.71M | 294.01M | 44.17M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 508.66M | 592.14M | 551.57M | 510.29M | 300.9M | 194.58M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 108.38M | 98.85M | 88.77M | 76.97M | 70.89M | 55.99M |
Shares Outstanding (Diluted) | 108.38M | 98.85M | 88.77M | 76.97M | 70.89M | 55.99M |
EPS (Basic) | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 |
EPS (Diluted) | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 |
EBITDA | -396.77M | -508.74M | -472.22M | -466.61M | -261M | -130.27M |
EBIT | -412.69M | -519.02M | -481.19M | -474.19M | -267.89M | -136.58M |
Depreciation & Amortization | 15.92M | 10.29M | 8.98M | 7.57M | 6.89M | 6.31M |
Add to Watchlist
Select watchlists to add or remove NTLA